 Connection
Mayumi Nakagawa to Papillomaviridae
This is a "connection" page, showing publications Mayumi Nakagawa has written about Papillomaviridae.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.434 |
|
|
|
-
Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019 Aug; 78:8-16.
Score: 0.651
-
Moerman-Herzog A, Nakagawa M. Early Defensive Mechanisms against Human Papillomavirus Infection. Clin Vaccine Immunol. 2015 Aug; 22(8):850-7.
Score: 0.491
-
Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol. 2015 Jul; 22(7):679-87.
Score: 0.488
-
Nakagawa M, Kim KH, Gillam TM, Moscicki AB. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol. 2007 Feb; 81(3):1412-23.
Score: 0.271
-
Nakagawa M, Kim KH, Moscicki AB. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol. 2005 Aug; 12(8):1003-5.
Score: 0.248
-
Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, Moscicki AB. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol. 2002 Jul; 9(4):877-82.
Score: 0.200
-
Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J Low Genit Tract Dis. 2010 Apr; 14(2):124-9.
Score: 0.086
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|